PL3233054T3 - Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego - Google Patents

Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego

Info

Publication number
PL3233054T3
PL3233054T3 PL15813578T PL15813578T PL3233054T3 PL 3233054 T3 PL3233054 T3 PL 3233054T3 PL 15813578 T PL15813578 T PL 15813578T PL 15813578 T PL15813578 T PL 15813578T PL 3233054 T3 PL3233054 T3 PL 3233054T3
Authority
PL
Poland
Prior art keywords
pi3k
mtor
formulations
inhibitor
intravenous administration
Prior art date
Application number
PL15813578T
Other languages
English (en)
Polish (pl)
Inventor
Kevin Richard Back
Michael Cram
Aidan James Harper
W. James Huang
Jonathan Richard Lillis
Timothy Michael Lukas
Sumit Luthra
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of PL3233054T3 publication Critical patent/PL3233054T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/17Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL15813578T 2014-12-17 2015-12-10 Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego PL3233054T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
EP15813578.0A EP3233054B1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
PL3233054T3 true PL3233054T3 (pl) 2021-12-20

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15813578T PL3233054T3 (pl) 2014-12-17 2015-12-10 Postacie użytkowe inhibitora PI3K/MTOR do podawania dożylnego

Country Status (25)

Country Link
US (2) US10172942B2 (enExample)
EP (1) EP3233054B1 (enExample)
JP (1) JP6420753B2 (enExample)
KR (1) KR102016822B1 (enExample)
CN (1) CN107205923B (enExample)
AU (1) AU2015365497B2 (enExample)
CA (1) CA2915199C (enExample)
CY (1) CY1124527T1 (enExample)
DK (1) DK3233054T3 (enExample)
ES (1) ES2881214T3 (enExample)
HR (1) HRP20211446T1 (enExample)
HU (1) HUE055928T2 (enExample)
IL (1) IL252158B (enExample)
LT (1) LT3233054T (enExample)
MX (1) MX380172B (enExample)
NZ (1) NZ731518A (enExample)
PL (1) PL3233054T3 (enExample)
PT (1) PT3233054T (enExample)
RS (1) RS62337B1 (enExample)
RU (1) RU2672875C1 (enExample)
SG (1) SG11201703826TA (enExample)
SI (1) SI3233054T1 (enExample)
TW (1) TWI660729B (enExample)
WO (1) WO2016097949A1 (enExample)
ZA (1) ZA201703764B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895370T3 (es) 2017-08-25 2022-02-21 Pfizer Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea
NZ805649A (en) * 2018-06-07 2024-11-29 Pfizer Aqueous formulation comprising 1-(4-{ [4-(dimethylamino)piperidin-1-yl]carbonyl} phenyl)-3- [4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
TW202320795A (zh) 2021-07-26 2023-06-01 美商凱爾科迪股份有限公司 使用1-(4-{[4-(二甲胺基)哌啶-1-基]羰基}苯基)-3-[4-(4,6-二嗎啉-4-基-1,3,5-三-2-基)苯基]脲治療癌症之方法
WO2025128712A1 (en) 2023-12-12 2025-06-19 Celcuity Inc. Treatment of ocular diseases using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl)phenyl)-3-[4-(4,6- dimorpholin-4- yl-1,3,5-triazin-2-yl)phenyl]urea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
MX2007014726A (es) * 2005-05-27 2008-02-14 Bayer Healthcare Ag Tratamiento combinado que comprende un compuesto diarilurea y una pi3, akt cinasa o inhibidores mtor (rapamicina) para tratamiento de cancer.
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
EP2300483A1 (en) * 2008-05-23 2011-03-30 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
US8158624B2 (en) * 2008-05-30 2012-04-17 Genetech, Inc. Purine PI3K inhibitor compounds and methods of use
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2014078522A1 (en) * 2012-11-14 2014-05-22 Ohio State Innovation Foundation Materials and methods useful for treating glioblastoma
EP2968191B1 (en) * 2013-03-14 2021-06-16 Abraxis BioScience, LLC Methods of treating bladder cancer
MX378984B (es) * 2014-03-14 2025-03-11 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.

Also Published As

Publication number Publication date
ES2881214T3 (es) 2021-11-29
JP2016113461A (ja) 2016-06-23
US10172942B2 (en) 2019-01-08
KR20170082638A (ko) 2017-07-14
SI3233054T1 (sl) 2021-11-30
HRP20211446T1 (hr) 2021-12-24
DK3233054T3 (da) 2021-08-02
AU2015365497A1 (en) 2017-06-01
US20190105390A1 (en) 2019-04-11
CA2915199C (en) 2018-11-06
RU2672875C1 (ru) 2018-11-20
SG11201703826TA (en) 2017-07-28
CN107205923B (zh) 2021-03-05
PT3233054T (pt) 2021-08-02
IL252158B (en) 2021-01-31
CA2915199A1 (en) 2016-06-17
AU2015365497B2 (en) 2020-07-02
US10660959B2 (en) 2020-05-26
IL252158A0 (en) 2017-07-31
CY1124527T1 (el) 2022-07-22
BR112017010841A2 (pt) 2017-12-26
JP6420753B2 (ja) 2018-11-07
ZA201703764B (en) 2020-11-25
CN107205923A (zh) 2017-09-26
US20170360935A1 (en) 2017-12-21
TW201632188A (zh) 2016-09-16
EP3233054A1 (en) 2017-10-25
HUE055928T2 (hu) 2022-01-28
NZ731518A (en) 2019-03-29
MX380172B (es) 2025-03-12
WO2016097949A1 (en) 2016-06-23
LT3233054T (lt) 2021-07-26
RS62337B1 (sr) 2021-10-29
MX2017008072A (es) 2017-09-28
TWI660729B (zh) 2019-06-01
KR102016822B1 (ko) 2019-08-30
EP3233054B1 (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL290729B2 (en) Proton-binding polymers for oral administration
DK3236943T3 (da) Sammensætninger til ileo-jejunal lægemiddeladministration
PT3237045T (pt) Dispositivo para administração de produtos medicinais
PT3191167T (pt) Válvula para administração de fluidos farmacêuticos
ZA201401683B (en) Pharmaceutical compositions for rectal administration
EP3256133A4 (en) Intravenous infusion dosage form
ZA201605263B (en) Pharmaceutical composition for topical administration
PL3191168T3 (pl) Zawór do podawania wielu płynów leczniczych
ZA201703562B (en) Pharmaceutical composition for oral administration comprising taxane
IL255853B (en) Nano-particles for use as a therapeutic vaccine
HRP20181968T1 (hr) Formulacije temeljene na melatoninu za parenteralno davanje
LT3226888T (lt) Selektyvaus il-6-trans-signalinio inhibitoriaus skyrimas
ZA201703764B (en) Formulations of a pi3k/mtor-inhibitor for intravenous administration
ZA201608785B (en) Nasal administration
GB201419540D0 (en) Delivery of drugs
EP3355888B8 (en) Hemi-synthetic trilobine analogs for use as a drug
GB201417589D0 (en) Pharmaceutical Formulations
PH32014000630S1 (en) Syringe for oral medication
HK1229386A1 (en) Administration regime
GB201403532D0 (en) Intravenous cannula
GB201407741D0 (en) Novel drug formulation
ZA201405476B (en) Anthelmintic medicament
GB201400951D0 (en) Novel drug formulation